Developing technologies in biodefense research: computational drug design

Abstract

The development of small-molecule drugs to counter the threat of bioterrorism will differ from classical drug discovery because it will be impossible to evaluate efficacy in clinical trials for many agents. This difference focuses biodefense on the identification of multiple drug candidates for each threat organism so that multiple treatments can be mounted simultaneously when needed to maximize the probability of success. Accordingly, drug discovery will become the rate-and cost-limiting phase of the overall drug development process. We address the potential of computational chemistry to optimize efficiency and efficacy in the discovery phase. The major elements required for a successful computational approach are the calculation of binding free energy, accounting for changes in solvation on ligand binding, and compensating for protein flexibility. Drug Dev Res 70 : 279-287, 2009. r

Global Current Trends in Drug Designing for Management of Type-2 Diabetes and Neurodegenerative Disorders

“…The completion of Human genome project has revolutionized the biomedical research and has had great impact on the basic biological research especially, in the area of genomics and proteomics that led to discovery of new drugs [45]. For such innovative drug discovery and design, a lot of genomics and proteomics experimental data are compared with established genomics and proteomics databases, with the help of computer software enabling quick and accurate searches within these databases.…”

New Perspectives on Innovative Drug Discovery: An Overview

“…Entering the 21 st century, the advent of biochemical techniques and cutting-edge technologies has made available a plethora of new approaches in drug design and invention. The utilization of biochemical assays (197), the employment of biomarkers (198), the exploitation of mathematical models (199,200), microarray gene-expression technologies (201), the operation of molecular imaging (202), pharmaceutical crystal engineering (203), the application of high speed synthesis technologies (204), computational drug design (205) including computational methodologies firmly rooted in statistical thermodynamics (206), as well as the adoption of genotoxicity testing (207) have greatly facilitated the selection and optimization of lead compounds. Recognition of macromolecular targets for therapeutic intervention (208) and the causal relationship between ubiquitin and human diseases (209) has also added new facets in drug discovery.…”